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Abstract
Background: Parkinson’s disease (PD)-associated E3 ubiquitin ligase Parkin is enriched at glutamatergic synapses,
where it ubiquitinates multiple substrates, suggesting that its mutation/loss-of-function could contribute to the
etiology of PD by disrupting excitatory neurotransmission. Here, we evaluate the impact of four common
PD-associated Parkin point mutations (T240M, R275W, R334C, G430D) on glutamatergic synaptic function in
hippocampal neurons.
Results: We find that expression of these point mutants in cultured hippocampal neurons from Parkin-deficient and
Parkin-null backgrounds alters NMDA and AMPA receptor-mediated currents and cell-surface levels and prevents the
induction of long-term depression. Mechanistically, we demonstrate that Parkin regulates NMDA receptor trafficking
through its ubiquitination of GluN1, and that all four mutants are impaired in this ubiquitinating activity. Furthermore,
Parkin regulates synaptic AMPA receptor trafficking via its binding and retention of the postsynaptic scaffold Homer1,
and all mutants are similarly impaired in this capacity.
Conclusion: Our findings demonstrate that pathogenic Parkin mutations disrupt glutamatergic synaptic transmission
in hippocampal neurons by impeding NMDA and AMPA receptor trafficking. Such effects may contribute to
the pathophysiology of PD in PARK2 patients.
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Background
Mutations in the PARK2 gene are the most common
cause of autosomal recessive juvenile parkinsonism and
a major contributor to familial and sporadic early-onset
Parkinson’s disease (PD) [1–4]. PARK2 encodes Parkin, a
RING-between-RING domain E3 ubiquitin ligase that
catalyzes the covalent attachment of ubiquitin to specific
substrates and regulates vital cellular processes including
mitochondrial quality control and apoptosis [5–7]. Al-
though it remains unclear how Parkin loss-of-function
precipitates the death of midbrain dopaminergic neurons
to cause PD, its ubiquitination of mitochondrial proteins
downstream of the kinase PINK1 has been shown to me-
diate mitophagy, a selective form of autophagy [8–11].
The buildup of damaged and dysfunctional mitochondria
promotes oxidative stress, to which dopaminergic neu-
rons are particularly vulnerable [12, 13], potentially
explaining one mechanism through which PARK2 muta-
tions induce dopaminergic cell loss and the motor symp-
toms of PD.
However, Parkin is highly expressed throughout the
brain and known to regulate other aspects of neuronal
function, including glutamatergic neurotransmission [14].
Indeed, defects in glutamatergic transmission and plasti-
city are reported at hippocampal and corticostriatal synap-
ses deficient in Parkin [15–20]. Parkin’s mechanisms of
action at excitatory synapses remain poorly understood,
although its ubiquitinating activity has been found to
regulate the stability and function of multiple synaptic
substrates, including the presynaptic vesicle-associated
protein synaptotagmins XI and IV, the postsynaptic
scaffold PICK1, and the kainate receptor subunit GluK2
[21–26]. Furthermore, our recent work demonstrates that
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Parkin also has a structural role at the synapse, linking
postsynaptic endocytic zones required for AMPA-type
glutamate receptor (AMPAR) capture and internalization
to the postsynaptic density through a direct interaction
with the scaffold protein Homer1 [19]. In Parkin-deficient
neurons, both the levels of postsynaptic Homer1 and the
density of endocytic zones are significantly reduced, lead-
ing to impaired AMPAR retention at synapses and ultim-
ately to decreased AMPAR-mediated currents [19].
Loss of these enzymatic and structural roles of Parkin
at glutamatergic synapses likely contributes to the symp-
toms and progression of PD in patients with PARK2 mu-
tations. Consistent with this concept, PD is recognized
as a multi-system disorder with both motor and
non-motor symptoms, including resting tremor, muscle
rigidity, disordered sleep, sensory dysfunction, depres-
sion, and cognitive impairment [27, 28]. Although some
of the > 200 pathogenic mutations, deletions, and exonic
rearrangements identified in PARK2 have been shown to
disrupt Parkin’s E3 ligase activity [29–32], their effects at
glutamatergic synapses, comprising the vast majority of
synapses in the brain, are almost completely unexplored.
Here, we evaluate the effects of four PD-associated
Parkin point mutations (T240M, R275W, R334C,
G430D) on neurotransmission and plasticity in hippo-
campal neurons, which are both rich sources of gluta-
matergic synapses as well as critical substrates for
learning and memory. We find that all four mutants
alter NMDA- and AMPA-type glutamate receptor traf-
ficking and signaling. Mechanistically, we identify
NMDA receptor (NMDAR) subunit GluN1 as a novel
Parkin substrate and find that the mutants are defective
in GluN1 ubiquitination, leading to decreased cell-sur-
face NMDAR levels. Furthermore, the mutants exhibit
reduced binding and synaptic retention of Homer1, lead-
ing to decreased cell-surface AMPAR levels and im-
paired AMPAR internalization during the induction of
synaptic depression. Taken together, these data demon-
strate that pathogenic Parkin mutations impair gluta-
matergic neurotransmission and plasticity, likely
contributing to the etiology of PARK2-associated PD.
Results
Pathogenic Parkin mutations alter AMPAR and NMDAR
cell-surface levels and currents
More than 200 pathogenic mutations have been identi-
fied in PARK2, comprising point mutations, deletions,
and exonic rearrangements that are associated with
early-onset PD and autosomal recessive juvenile PD [5,
33, 34]. However, few of these have been evaluated for
their impact on excitatory synapse function. We exam-
ined four of the most prevalent Parkin point mutations,
collectively identified in ~ 100 families worldwide
(Parkinson Disease Mutation Database) and located
across three domains of Parkin (T240M and R275W in
the RING1 domain; R334C in the IBR domain; G430D in
the RING2 domain) [3, 35–37](Additional file 1: Figure
S1a). We first assessed the expression and subcellular
localization of these mutants in cultured hippocampal
neurons from either the Parkin knockdown background
(i.e., lentivirally transduced on 2 days in vitro (DIV) with
an shRNA against rat Parkin (shParkin), previously shown
to reduce Parkin levels by ~ 50% [19]), or Parkin knockout
background (i.e., cultured from KO rats; SAGE/Horizon
Discovery). GFP-tagged T240M, R275W, R334C, and
G430D human Parkin constructs exhibited similar subcel-
lular localizations to GFP-wild-type (WT) Parkin, and
three of these mutants were expressed at similar levels
(Fig. 1; Additional file 1: Figure S1b–d). G430D expression
was somewhat higher in the knockdown background
(Additional file 1: Figure S1b, d), perhaps reflecting a defi-
ciency in Parkin auto-ubiquitination and degradation for
this mutant.
We previously reported that Parkin knockdown/knock-
out decreased cell-surface AMPA receptor (AMPAR)
levels, and that co-expression of WT-Parkin (shPar-
kin-WT) rescued this phenotype to the level of GFP-ex-
pressing control neurons [19]. We therefore assessed
whether expression of each of the four Parkin mutants
could similarly rescue cell-surface AMPAR levels. As in
our previous study, we observed that shParkin decreased
GluA1 levels by nearly 20% compared to GFP or
shParkin-WT expression (Fig. 1a, b). None of the four
mutants could match WT Parkin restoration of GluA1
levels, although both T240M and R334C were able to par-
tially rescue this phenotype (Fig. 1a, b). To rule out the
ability of the mutants to act as dominant-negatives on en-
dogenous Parkin, we also examined their effects in the
KO background. Here, the mutants were similarly unable
to increase surface GluA1 levels above those observed in
the KO condition, while WT Parkin expression increased
GluA1 levels by 20% (Fig. 1c, d), equivalent to its level of
rescue in knockdown neurons (Fig. 1a, b). Moreover, ex-
pression of shParkin in the KO neurons did not further re-
duce or alter GluA1 levels (Fig. 1c, d), indicating its lack
of off-target effects.
Given Parkin’s reported ability to regulate other glutam-
ate receptor types (e.g., kainate) via ubiquitination [26], we
also examined cell-surface NMDA receptor levels in these
neurons by immunostaining with a human-derived anti-
body against the GluN1 subunit [38]. Intriguingly, we ob-
served that shParkin similarly reduced cell-surface GluN1
levels (by ~ 15%) compared to GFP or shParkin-WT ex-
pression (Fig. 2a, b). Again, three of the mutants (R334C,
R275W, G430D) were unable to rescue this phenotype,
while T240M rescued to the level of WT Parkin (Fig. 2a,
b). These experiments were also performed in Parkin KO
neurons, where it was confirmed that none of the
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mutants, including T240M, was able to increase surface
GluN1 levels above those observed in the KO or KO +
shParkin conditions (Fig. 2c, d). In contrast, WT Parkin
expression increased GluN1 levels by ~ 20%, similar to its
level of rescue in shParkin-expressing neurons (Fig. 2c, d).
Together, these findings indicate that none of the four
Parkin mutants are able to support normal cell-surface
AMPAR and NMDAR levels.
To determine whether the Parkin mutants comprom-
ise excitatory neurotransmission, we examined their ef-
fects on AMPA and NMDA receptor spontaneous
excitatory postsynaptic currents (EPSCs) in both Parkin
knockdown and KO neurons. We compared the degree
of rescue from expression of Parkin mutants to that of
WT Parkin, which significantly increased AMPAR mini-





























































































































































































Fig. 1 Parkin mutation/loss-of-function decreases cell-surface GluA1 levels. a Representative images of surface GluA1 staining (red) in 14–16 DIV
hippocampal neurons expressing GFP, shParkin, shParkin-WT, shParkin-T240M, shParkin-R275W, shParkin-R334C, or shParkin-G430D constructs.
Scale bar, 10 μm. b Quantification of cell-surface GluA1 intensity expressed as a fraction of shParkin-WT (n≥ 70 fields of view per condition with > 100
GluA1 puncta per field, results confirmed in 4 independent experiments. ***P < 0.001, one-way ANOVA, error bars represent SEM). c Representative
images of surface GluA1 staining (red) in 14–16 DIV Parkin KO hippocampal neurons expressing shParkin, shParkin-WT, shParkin-T240M, shParkin-
R275W, shParkin-R334C, or shParkin-G430D constructs and non-transduced KO control. Scale bar, 10 μm. d Quantification of cell-surface GluA1 intensity
expressed as a fraction of Parkin KO (n ≥ 50 fields of view per condition with > 100 GluA1 puncta per field, results confirmed in 2 independent
experiments. ***P < 0.001, one-way ANOVA, error bars represent SEM)
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KO backgrounds (Fig. 3a, b, d, e), consistent with our
previous findings [19] and results with cell-surface
GluA1 immunostaining (Fig. 1). WT Parkin expression
also increased mEPSC frequency in the KO but not
knockdown background (Fig. 3a, c, d, f ), as expected
given our previous results showing that AMPAR mEPSC
frequency was decreased in Parkin KO but not knock-
down neurons [19]. In contrast, none of the Parkin
mutants was able to increase mEPSC amplitude above
knockdown or KO levels, and none rescued mEPSC fre-
quency in KO neurons, although T240M and R275W
did have small but significant effects on frequency in the
knockdown background (Fig. 3a–f ).
We also examined spontaneous EPSC amplitudes for
NMDARs (NMDAR-EPSCs) in both Parkin knockdown

























































































































































































Fig. 2 Parkin mutation/loss-of-function decreases cell-surface GluN1 levels. a Representative images of surface GluN1 staining (red) in 14–16 DIV
hippocampal neurons expressing GFP, shParkin, shParkin-WT, shParkin-T240M, shParkin-R275W, shParkin-R334C, or shParkin-G430D constructs.
Scale bar, 10 μm. b Quantification of cell-surface GluN1 intensity expressed as a fraction of shParkin-WT (n ≥ 50 fields of view per condition with
> 100 GluN1 puncta per field, results confirmed in 4 independent experiments. ***P < 0.001, one-way ANOVA, error bars represent SEM). Scale bar,
10 μm. c Representative images of surface GluN1 staining (red) in 14–16 DIV Parkin KO hippocampal neurons expressing shParkin, shParkin-WT,
shParkin-T240M, shParkin-R275W, shParkin-R334C or shParkin-G430D constructs, and non-transduced KO control. Scale bar, 10 μm. d Quantification of
cell-surface GluN1 intensity expressed as a fraction of Parkin KO (n ≥ 50 fields of view per condition with > 100 GluA1 puncta per field,
results confirmed in 2 independent experiments. ***P < 0.001, one-way ANOVA, error bars represent SEM)
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Fig. 3 (See legend on next page.)
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expression significantly increased NMDAR-EPSCs in both
of these backgrounds (Fig. 3g–j), indicative of the reduction
in synaptic NMDAR levels in the absence of Parkin. Again,
the four Parkin mutants were unable to recapitulate WT
Parkin function and did not increase NMDAR-EPSC ampli-
tudes above knockdown/KO levels (Fig. 3g–j). To further
confirm this loss of NMDARs in the Parkin-deficient
background, we measured whole cell NMDAR currents in
response to local application of NMDA for neurons ex-
pressing soluble GFP, human Parkin (Hu-Parkin), shParkin,
or shParkin-WT (Additional file 2: Figure S2a), as well as
the levels of NMDAR subunits (GluN1, GluN2A, and
GluN2B) by cell-surface biotinylation (Additional file 2:
Figure S2b and S2c). We observed that shParkin signifi-
cantly reduced both NMDAR currents and surface GluN
subunit biotinylation (Additional file 2: Figure S2), confirm-
ing by several methods that Parkin regulates cell-surface
NMDAR levels.
Parkin’s E3 ligase activity is required for maintaining
surface NMDAR but not AMPAR levels
We next investigated the mechanisms through which
these pathogenic mutations disrupt cell-surface AMPAR
and NMDAR expression. Each mutant is reported or pre-
dicted to impair Parkin’s E3 ligase activity [29, 30, 32], sug-
gesting that the loss of Parkin-mediated ubiquitination
leads to a reduction of cell-surface glutamate receptor
levels. To test this, we took advantage of two mutants
engineered to augment or inhibit Parkin-mediated ubiqui-
tination. In particular, mutation of tryptophan 403 to ala-
nine (W403A) was shown to increase Parkin’s E3 ligase
activity, and mutation of cysteine 431 to serine (C431S) to
inhibit this activity [29](Additional file 1: Figure S1a). As
in previous experiments, we expressed WT, W403A, or
C431S Parkin together with shParkin in hippocampal neu-
rons, and after verifying their expression (Additional file 1:
Figure S1e), immunostained with GluN1 or GluA1 anti-
bodies. Unexpectedly, we found that both W403A and
C431S mutants efficiently restored surface GluA1 to WT
Parkin levels (Fig. 4a, c), while only W403A rescued sur-
face GluN1 levels (Fig. 4b, d). These findings demonstrate
that Parkin’s E3 ligase activity is essential for maintaining
cell-surface NMDAR but not AMPAR levels, and indicate
that Parkin regulates each receptor type through a distinct
mechanism. Further supporting this concept, we found
that overexpression of the postsynaptic scaffold Homer1,
previously shown to rescue surface GluA1 levels in
Parkin-deficient neurons, did not rescue surface GluN1
levels (Additional file 3: Figure S3).
Parkin mutants are deficient in ubiquitination of NMDAR
subunit GluN1
To determine whether Parkin regulation of surface
NMDAR levels is mediated through direct ubiquitination
of NMDAR subunits, we performed ubiquitination assays
in HEK293T cells co-transfected with GFP-tagged
NMDAR or AMPAR subunits (GluN1, GluN2B, GluA1,
GluA2) together with HA-ubiquitin, Myc vector control
or Myc-Parkin. Here, we found that Parkin co-expression
significantly increased ubiquitination of GFP-GluN1
(Fig. 5a, b), and that a similar degree of GluN1 ubiquitina-
tion was observed following its immunoprecipitation
under denaturing conditions (1% SDS) to eliminate other
potential binding partners (Additional file 4: Figure S4a,
b). In contrast, the other glutamate receptor subunits had
ubiquitination levels equivalent to that of GFP control
(Fig. 5a, b). Follow-up co-immunoprecipitation assays
revealed that GluN1 was also the only subunit to
co-precipitate with Myc-Parkin (Fig. 5c). These data dem-
onstrate that Parkin specifically interacts with and ubiqui-
tinates the GluN1 subunit of NMDARs.
To evaluate whether the GFP-tagged Parkin mutants
were impaired in their ability to ubiquitinate GluN1, we
performed ubiquitination assays using Flag-GluN1. We
first tested the sensitivity of the assay by examining
GluN1 ubiquitination by the W403A (active) and C431S
(inactive) Parkin mutants. Here, we found that W403A
increased GluN1 ubiquitination compared to WT
(See figure on previous page.)
Fig. 3 Parkin mutation/loss-of-function decreases AMPA and NMDA receptor-mediated currents. a Representative traces of spontaneous AMPAR
mEPSCs from 14 to 16 DIV hippocampal neurons transduced with shParkin +/− WT Parkin or T240M/R275W/R334C/G430D mutants. b, c Quantification
of mEPSC amplitude (b) and frequency (c) for the six conditions (n = 14 for shParkin, shParkin-WT and shParkin-T240M, 10 for shParkin-R334C, 8 for
shParkin-R275W and shParkin-G430D; *P < 0.05, **P < 0.005, ***P < 0.001, one-way ANOVA, error bars represent SEM). d Representative traces of
spontaneous AMPAR mEPSCs from 14 to 16 DIV Parkin KO hippocampal neurons transduced with shParkin +/− WT Parkin or T240M/R275W/R334C/
G430D mutants and non-transduced KO control. e, f Quantification of mEPSC amplitude (e) and frequency (f) for the seven conditions (n = 12 for
shParkin-WT and shParkin-T240M, 11 for shParkin-R275W and shParkin-G430D, 10 for shParkin-R334C, 8 for shParkin and non-transduced KO control;
*P < 0.05, **P < 0.005, ***P < 0.001, one-way ANOVA, error bars represent SEM). g Representative traces of NMDAR currents (NMDAR-EPSC) from 14 to
16 DIV hippocampal neurons transduced with shParkin +/− WT Parkin or T240M/R275W/R334C/G430D mutants. h Quantification of NMDAR-EPSC
amplitude for the six conditions (n = 10 for shParkin-T240M and shParkin-R334C, 8 for shParkin, shParkin-WT, shParkin-R275W and shParkin-G430D;
**P < 0.005, ***P < 0.001, one-way ANOVA, error bars represent SEM). i Representative traces of NMDAR currents (NMDA-EPSC) from 14 to 16 DIV Parkin
KO hippocampal neurons transduced with shParkin +/− WT Parkin or T240M/R275W/R334C/G430D mutants and non-transduced KO control. j
Quantification of NMDAR-EPSC amplitude for the seven conditions (n = 12 for shParkin-WT and shParkin-T240M, 11 for shParkin-G430D, 10 for shParkin-
R334C and shParkin-R275W, 8 for shParkin and non-transduced KO control; **P < 0.005, ***P < 0.001, one-way ANOVA, error bars represent SEM)
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Parkin, while ubiquitination by C431S was indistinguish-
able from soluble GFP control (Fig. 5d, e). We next ex-
amined Flag-GluN1 ubiquitination in the presence of
T240M, R275W, R334C, and G430D and found the
levels of ubiquitin immunoreactivity to be similar to


























































































































Fig. 4 Parkin E3 ligase activity is required to maintain cell-surface NMDARs but not AMPARs. a Representative images of surface GluA1 staining
(red) in 14–16 DIV hippocampal neurons expressing shParkin +/− WT, C431S, or W403A Parkin constructs. Scale bar, 10 μm. b Same condition as
(a), but for surface GluN1 staining (red). Scale bar, 10 μm. c Quantification of cell- surface GluA1 intensity expressed as a fraction of shParkin
control (n≥ 40 fields of view per condition with > 100 GluA1 puncta per field, results confirmed in 3 independent experiments. ***P < 0.001,
one-way ANOVA, error bars represent SEM). d Quantification of cell-surface GluN1 intensity expressed as a fraction of shParkin control (n ≥ 40
fields of view per condition with > 100 GluN1 puncta per field, results confirmed in 3 independent experiments. ***P < 0.001, one-way ANOVA,
error bars represent SEM)
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Fig. 5 Parkin-mediated GluN1 ubiquitination is impaired in pathogenic mutants. a Representative immunoblots for GFP immunoprecipitation (IP)
from HEK293T cell lysates expressing Myc/Myc-Parkin, GFP-GluA1/-GluA2/-GluN1/-GluN2B, and HA-ubiquitin, probed for HA and GFP. Ubiquitin
immunoreactivity used for quantification is marked on HA blots. b Quantification of GFP-GluA or GluN ubiquitination, expressed as the ratio of
marked HA blot intensity (a) with Myc-Parkin (+) to Myc control (−), then normalized to immunoprecipitated GFP, GFP-GluA or GluN (n = 3
experiments, *P < 0.05; one-way ANOVA, error bars represent SEM). c Representative Myc and GFP immunoblots for Myc IP from HEK293T cell
lysates expressing Myc-Parkin and GFP-GluA1/-GluA2/-GluN1/-GluN2B. Arrowhead indicates immunoprecipitated Myc-Parkin (just below IgG
band). d Representative HA and Flag immunoblots for Flag IP from HEK293T cell lysates expressing Flag-GluN1, GFP control/GFP-Parkin WT/
C431S/W403A, and HA-ubiquitin. Arrowhead indicates immunoprecipitated Flag-GluN1. Ubiquitin immunoreactivity used for quantification is
marked on HA blots. e Quantification of Flag-GluN1 ubiquitination by measurement of marked HA blot intensity (d), normalized to immunoprecipitated
Flag-GluN1 and reported as a fraction of GFP control (n = 3 experiments, **P < 0.01, ***P < 0.001, one-way ANOVA, error bars represent
SEM). f Representative HA and Flag immunoblots for Flag IP from HEK293T cell lysates expressing Flag-GluN1, GFP control/GFP-Parkin WT/
T240M/R275W/R334C/G430D constructs, and HA-ubiquitin. Arrowhead indicates immunoprecipitated Flag-GluN1. Ubiquitin immunoreactivity used
for quantification is marked on HA blots. g Quantification of Flag-GluN1 ubiquitination by measurement of marked HA intensity (f), normalized to
immunoprecipitated Flag-GluN1 and reported as a fraction of GFP condition (n = 3 experiments, *P < 0.05; **P < 0.01, ***P < 0.001, one-way ANOVA,
error bars represent SEM)
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confirming that these Parkin mutants are deficient in
their ubiquitination of GluN1.
Parkin regulates NMDAR internalization and recycling
Ubiquitination is known to mediate protein degradation,
and Parkin-mediated ubiquitination regulates the stabil-
ity and degradation of multiple synaptic substrates [21–
24, 26]. However, since cell-surface GluN1 levels were
decreased rather than increased following Parkin
loss-of-function, we hypothesized that Parkin-mediated
ubiquitination does not regulate NMDAR degradation.
This hypothesis was confirmed by cycloheximide-chase
experiments to compare the degradation of NMDAR
subunits (GluN1, GluN2A, GluN2B) in control neurons
with those expressing shParkin +/− WT Parkin
(Additional file 4: Figure S4c, d). Since ubiquitination
also regulates glutamate receptor trafficking [39–41], we
utilized antibody feeding assays to monitor the internal-
ization and recycling of GluN1 in neurons expressing
soluble GFP or shParkin +/− WT-Parkin (see the
“Methods” section for details). Here, we found that both
the internalization of GluN1 and its recycling back to
the cell-surface were significantly impaired in Parkin
knockdown neurons and that these defects were fully
rescued by WT Parkin (Fig. 6a–d). Altogether, these
findings indicate that Parkin-mediated ubiquitination
regulates both the endocytosis and exocytosis of
NMDARs at the cell-surface, leading to an overall reduc-
tion of surface NMDARs in Parkin-deficient neurons.
Parkin mutants are impaired in their binding and
retention of postsynaptic Homer1
Although defective GluN1 ubiquitination provides a
mechanistic explanation for how Parkin mutants decrease
cell-surface NMDAR levels, it does not explain how these
mutants decrease cell-surface AMPAR levels, a phenotype
that does not appear to depend on Parkin’s ubiquitinating
activity (see Fig. 4). We previously showed that direct
binding of Parkin to Homer1 is necessary for maintaining
surface AMPAR levels, by tethering endocytic zones (EZs)
for AMPAR capture and internalization to the postsynap-
tic density [19]. In Parkin-deficient neurons, Homer1
levels are decreased, leading to reduced EZ density and
loss of synaptic AMPARs [19]. To determine whether the
Parkin mutants were impaired in their binding to
Homer1, we performed co-immunoprecipitation assays in
HEK293T cells co-expressing GFP-tagged Homer1 and ei-
ther T240M, R275W, R334C, or G430D. Intriguingly, all
of the mutants exhibited significantly less co-precipitation
with Homer1 than did WT Parkin (Fig. 7a, b), reinforcing
the link between Parkin/Homer1 binding and surface
GluA1 levels. We also performed quantitative immuno-
fluorescence microscopy to measure synaptic Homer1
levels in knockdown neurons expressing WT Parkin or
each mutant. Here, we found that synaptic Homer1 levels
were significantly decreased in the presence of all four
mutants compared to WT Parkin (Fig. 7c, d), consistent
with our immunostaining and electrophysiology data
showing decreased cell-surface AMPARs and mEPSC am-
plitudes (Figs. 1 and 3). Together, these findings provide
an explanation for how Parkin mutations disrupt synaptic
AMPAR levels and AMPAR-mediated currents.
Parkin-mediated AMPAR internalization is required for
induction of synaptic depression
NMDAR-dependent synaptic plasticity mechanisms, in-
cluding long-term potentiation (LTP) and long-term de-
pression (LTD), are responsible for dynamic changes in
synaptic strength that mediate important high-order brain
functions such as learning and memory, pain perception,
addictive behaviors, and mood regulation [42–44]. Induc-
tion of LTP and LTD require rapid, calcium-mediated
changes in the number, phosphorylation state, and/or
subunit composition of synaptic cell-surface AMPARs [45,
46]. Since we identified clear roles for Parkin in AMPAR
and NMDAR trafficking, we hypothesized that Parkin
mutation or loss-of-function would impair these synaptic
plasticity mechanisms. Indeed, a previous study reported
that Parkin KO animals exhibit reduced hippocampal LTP
[20]. To test this possibility, we first examined NMDAR-
dependent synaptic potentiation and depression in
hippocampal neurons expressing soluble GFP or shParkin
+/− WT Parkin, using chemical stimuli to induce LTP or
LTD (cLTP or cLTD; see the “Methods” section and [47,
48]). Following these treatments, we calculated the ratio
of mean surface GluA1 intensity following cLTP or cLTD
induction to that in the untreated control condition, with
values > 1 representing insertion of GluA1-containing
AMPARs at the cell surface (i.e., successful cLTP), and
values < 1 representing internalization of AMPARs from
the surface (i.e., successful cLTD). Surprisingly, we found
that the magnitude of cLTP was nearly identical for GFP
control and shParkin-expressing neurons, although both
the basal and potentiated levels of surface GluA1 were
lower in knockdown neurons than in control neurons
(Fig. 8a, b). On the other hand, co-expression of WT Par-
kin led to a slight impairment of cLTP induction, likely
due to occlusion from higher initial surface levels of
GluA1 (Fig. 8a, b). In contrast, Parkin knockdown
completely prevented the induction of cLTD, and this
phenotype was fully restored by WT Parkin expres-
sion (Fig. 8c, d). These data are consistent with our
previous findings that Parkin regulates AMPAR endo-
cytosis but not exocytosis [19].
We next evaluated whether co-expression of Parkin
mutants could rescue this cLTD deficit. Remarkably, we
found that none of the four mutants were able to rescue
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GluA1 internalization following cLTD induction (Fig. 8e,
f ), consistent with their reduced Homer1 binding and
inability to rescue synaptic Homer1 levels compared to
WT Parkin (Fig. 7). Supporting the concept that Parkin
mutation/loss-of-function prevents LTD induction by
disrupting Homer1-linked endocytic zones and thus
GluA1 internalization, we found that dephosphorylation
of GluA1 at Serine-845, a hallmark of LTD that is
dependent upon events upstream of AMPAR internaliza-
tion (i.e., Ca2+ influx through NMDARs, phosphatase
activation; [47]), was unaffected by Parkin knockdown or
mutant co-expression (Additional file 5: Figure S5).
These findings indicate that pathogenic Parkin muta-
tions disrupt synaptic depression by impairing AMPAR
internalization.
Since hippocampal LTP was reported to be deficient in
Parkin KO animals [20], we also examined cLTP induc-
tion in hippocampal neurons from the Parkin KO back-
ground, in the presence or absence of WT Parkin or the
four mutants. We found that the magnitude of cLTP
0 min internalization 15 min internalization 
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internalized GluN1 
Fig. 6 Parkin deficiency impairs GluN1 internalization and recycling. a Representative images of 14–16 DIV hippocampal neurons expressing
soluble GFP control/shParkin/shParkin-WT constructs, immunostained for cell surface (surf) and internalized (inter) GluN1 after 0 and 15 min
internalization at 37 °C. Scale bars, 10 μm. b Representative images of 14–16 DIV hippocampal neurons expressing the same constructs
as in (a), immunostained for cell surface (surf) and recycled (rec’d) GluN1 after 30 min internalization followed by 0 and 60 min recycling
at 37 °C. Scale bars, 10 μm. c Quantification of GluN1 internalization at 15 min, expressed as the ratio of internalized to cell surface
GluN1 and normalized to GFP control condition (n ≥ 50 fields of view per condition with > 50 GluN1 puncta per field, results confirmed
in 3 independent experiments; ***P < 0.001, unpaired t test, error bars represent SEM). d Quantification of GluN1 recycling at 60 min,
expressed as the ratio of recycled to internalized GluN1 and normalized to GFP control condition (n ≥ 55 fields of view per condition
with > 50 GluN1 puncta per field, results confirmed in 3 independent experiments; ***P < 0.001, unpaired t test, error bars represent SEM)
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induction as measured by surface GluA1 levels was
indistinguishable in KO neurons compared to those ex-
pressing WT or mutant Parkin (Fig. 9a, b), again demon-
strating that Parkin loss-of-function does not impair
LTP. However, induction of cLTD was completely
blocked in KO neurons, and this phenotype was rescued
only by WT Parkin expression (Fig. 9c, d), indicating
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Fig. 7 Parkin mutations reduce Homer1 binding and synaptic retention. a Representative Parkin and Homer1 immunoblots for Homer1 IP from
HEK293T cell lysates expressing GFP-Homer1 and GFP-Parkin WT/T240M/R275W/R334C/G430D. b Quantification of Homer1/Parkin interaction by
measurement of co-immunoprecipitated GFP-Parkin WT/T240M/R275W/R334C/G430D, normalized to immunoprecipitated GFP-Homer1 and
reported as a fraction of GFP-Parkin WT condition (n = 3 experiments, one-way ANOVA, *P < 0.05, **P < 0.01, error bars represent SEM).
c Representative images of Homer1 (red) and VAMP2 (blue) staining in 14–16 DIV hippocampal neurons expressing GFP, shParkin, or
shParkin-WT/-T240M/-R275W/-R334C/-G430D. Arrows indicate representative synaptic Homer1 puncta (based on co-localization with
VAMP2) for each condition. Scale bar, 10 μm. d Quantification of synaptic Homer1 intensity at VAMP2-immunopositive puncta along
dendrites, expressed as a fraction of shParkin-WT control condition (n ≥ 50 fields of view per condition with > 50 co-localized Homer1
puncta per field, results confirmed in 3 independent experiments; ***P < 0.001, one-way ANOVA, error bars represent SEM)
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Parkin-deficient or Parkin-null backgrounds. Together,
these findings indicate that Parkin mediates NMDAR-
dependent synaptic depression by facilitating AMPAR
internalization and that pathogenic Parkin mutations
prevent this function.
Discussion
PARK2 mutations are present in > 3% of PD patients,
making them more prevalent than mutations in LRRK2
or α-synuclein [36, 37, 49–51]. Moreover, PD is a multi-
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shParkinControl shParkin-WTshParkinControl shParkin-WT
shParkin-G430DshParkinR275W shParkin-R275W shParkin-G430D
Fig. 8 Parkin mutation/knockdown impairs the induction of LTD. a Representative images of surface GluA1 staining (red) in 14–16 DIV hippocampal
neurons expressing GFP, shParkin or shParkin-WT, under the control condition (no treatment) or after chemical LTP (cLTP) induction. Scale bar, 10 μm.
b Quantification of the ratio of GluA1 intensity after cLTP induction to the control condition for neurons expressing GFP, shParkin, or shParkin-WT. c
Same as (a), but for control condition or chemical LTD (cLTD) induction. Scale bar, 10 μm. d Quantification of the ratio of GluA1 intensity after cLTD
induction to the control condition for neurons expressing GFP, shParkin, or shParkin-WT. e Representative images of surface GluA1 staining
(red) in 14–16 DIV hippocampal neurons expressing GFP, shParkin or shParkin-WT/-T240M/-R275W/-R334C/-G430D constructs, under the
control condition or after cLTD induction. Scale bar, 10 μm. f Quantification of the ratio of GluA1 intensity after cLTD induction to the control
condition for neurons expressing GFP, shParkin or shParkin-WT/-T240M/-R275W/-R334C/-G430D constructs. For panels (b) and (d), n ≥ 50 fields
of view per condition with > 100 GluA1 puncta per field, results confirmed in 3 independent experiments. ***P < 0.001, unpaired t test. For
panel (f), n ≥ 40 fields of view per condition with > 100 GluA1 puncta per field, results confirmed in 3 independent experiments. ***P < 0.001,
one-way ANOVA, error bars represent SEM
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densities (PSDs) of glutamatergic synapses, suggesting
that PARK2 mutations could contribute to PD patho-
physiology by disrupting excitatory neurotransmission.
Here, we demonstrate that expression of four PD-linked
Parkin mutations (T240M, R275W, R334C, and G430D)
in Parkin-deficient or Parkin-null backgrounds, to simu-
late its heterozygous or homozygous loss-of-function,
alters glutamatergic synaptic transmission and plasticity.
We provide mechanistic insight into how these Parkin
mutations impair NMDAR and AMPAR-mediated sig-
naling, through deficient ubiquitination of GluN1 and
deficient binding/retention of postsynaptic Homer1,
leading to reduced cell-surface NMDAR and AMPAR
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Fig. 9 Parkin mutation/knockout impairs the induction of LTD but not LTP. a Representative images of surface GluA1 staining (red) in 14–16 DIV
Parkin KO hippocampal neurons expressing shParkin or shParkin-WT/-T240M/-R275W/-R334C/-G430D constructs, and non-transduced KO control
under the control condition (no treatment) or after chemical LTP (cLTP) induction. Scale bar, 10 μm. b Quantification of the ratio of GluA1 intensity
after cLTP induction to the control condition for neurons expressing the above Parkin constructs. c Same as (a), but for control condition or chemical
LTD (cLTD) induction. Scale bar, 10 μm. d Quantification of the ratio of GluA1 intensity after cLTD induction to the control condition for neurons
expressing above Parkin constructs. For panels (b) and (d), n≥ 40 fields of view per condition with > 100 GluA1 puncta per field, results confirmed in 2
independent experiments. ***P < 0.001, one-way ANOVA, error bars represent SEM
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findings not only demonstrate that Parkin regulates post-
synaptic NMDA- and AMPA-type glutamate receptors
through distinct mechanisms, but also that common
PD-linked mutations disrupt both functions. Furthermore,
these studies show that even partial loss of Parkin function
significantly alters excitatory neurotransmission and plas-
ticity, suggesting that heterozygous PARK2 mutations also
impair these processes.
Although multiple studies show that Parkin regulates
glutamatergic neurotransmission, it is currently unclear
how its loss-of-function impacts excitatory drive in the
brain. Several studies report that Parkin mutation/
loss-of-function increases AMPAR and kainate receptor
(KAR)-mediated currents in neurons, enhances glutam-
ate excitotoxicity, and increases KAR and NMDAR
levels in several brain regions [14, 17, 26, 52]. These
findings have led to the hypothesis that Parkin
loss-of-function increases postsynaptic glutamate recep-
tor levels and currents, promoting the death of dopa-
minergic neurons by excitotoxicity [14, 52]. However,
other groups report that Parkin mutation/loss-of-func-
tion decreases neuronal excitability and/or AMPAR
EPSCs, as well as AMPAR levels in brain tissue from
knockout mice and human patients [15, 16, 19, 26, 52,
53]. We similarly find that Parkin loss-of-function de-
creases AMPAR- and NMDAR-mediated currents and
cell-surface levels, suggesting that pathogenic Parkin
mutations may reduce basal excitatory drive. On the
other hand, our finding that Parkin deficiency/loss-of--
function prevents the induction of LTD in hippocampal
neurons, potentially leading to an inability to weaken or
depotentiate glutamatergic synapses, lends support to
the concept of increased excitation or altered excitatory/
inhibitory balance in brains lacking Parkin.
Hippocampal NMDAR-dependent LTP is reportedly
impaired in Parkin KO mice [20], and we find that
cell-surface NMDAR levels are significantly reduced in
neurons lacking enzymatically active Parkin due to its
knockdown/KO or mutation, suggesting that synaptic
plasticity mechanisms could be broadly disrupted. How-
ever, we find that LTP induction is intact in hippocampal
neurons lacking functional Parkin, but that LTD is im-
paired. These findings suggest that the decrease in sur-
face NMDARs does not disrupt all NMDAR-dependent
plasticity mechanisms, although it may lead to more
subtle deficits in LTP that we cannot detect in our ana-
lyses. These findings are also consistent with our previous
work showing that Parkin is not required for AMPAR
exocytosis, but is an important regulator of AMPAR endo-
cytosis through its stabilization of Homer1-linked endocy-
tic zones [19]. Interestingly, none of the four Parkin
mutants evaluated in this study were able to rescue either
postsynaptic Homer1 levels or LTD induction, and all ex-
hibited significantly reduced Homer1 binding capacity.
These findings suggest that Parkin’s ability to mediate
AMPAR internalization during LTD induction is inter-
twined with its ability to interact with and maintain
Homer1 at the PSD.
PARK2-linked PD is often considered a distinct disease
from idiopathic or other genetic forms of PD, with earl-
ier onset, slower progression, and more purely motoric
symptoms [7, 54]. Consistent with these clinical pheno-
types, PARK2 patient brains lack widespread pathology,
including the Lewy bodies found in other forms of PD,
and cell loss is restricted to dopaminergic neurons of the
substantia nigra [7]. Predominantly glutamatergic brain
regions, including the hippocampus, are not primarily
affected or implicated in this form of PD. However,
PARK2 patients and heterozygous PARK2 mutation car-
riers are reported to exhibit higher rates of neuropsychi-
atric symptoms (e.g., depression, psychosis, panic attacks)
than non-carriers [7, 54, 55], and there is a significant
association between PARK2 heterozygosity and obsessive-
compulsive disorder [56]. While these disorders are asso-
ciated with altered dopaminergic signaling, they are also
strongly linked to changes in glutamatergic neurotrans-
mission, including decreased AMPAR and NMDAR levels
in specific brain regions [57–60]. PARK2 patients also ex-
hibit unusual sensitivity to L-dopa treatment and rapid de-
velopment of L-dopa-induced dyskinesia. Interestingly,
dyskinesia in animal models and PD patients is linked to
impaired glutamatergic synaptic plasticity, and in particu-
lar to the inability of synapses to become depotentiated/
depressed following L-dopa-induced potentiation [61–63].
Our findings that Parkin-deficient excitatory synapses can
become potentiated but not depressed, and that patho-
genic Parkin mutations similarly do not support the in-
duction of NMDAR-dependent LTD, may provide an
explanation for the development of dyskinesia in PARK2
patients. Furthermore, increased potentiation of excitatory
synapses would lead to higher levels of cell-surface
AMPARs, potentially hastening the death of already-
vulnerable dopaminergic neurons by glutamate excitotoxi-
city and thereby contributing to the early onset of motor
symptoms in PARK2 patients. It is also worth noting that
recent genome-wide association studies link PARK2 dele-
tions and copy number variations to autism, schizophre-
nia, and intellectual disability [33, 64–66], disorders
commonly associated with dysfunction of glutamatergic
synapses. Such findings highlight the need for further in-
vestigation of Parkin’s role in excitatory neurotransmis-
sion, and in particular how disruption of glutamatergic
signaling due to its loss-of-function may contribute to the
pathophysiology of PD and other brain disorders.
Conclusions
Together, our studies implicate glutamatergic synaptic
dysfunction in the etiology of motor and non-motor
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symptoms experienced by PARK2 patients. Moreover,
given the recent link between PARK2 copy number
variation and neurodevelopmental disorders, our find-
ings further underscore the importance of elucidating
Parkin’s molecular mechanisms of action at gluta-
matergic synapses, both to facilitate the development
of better treatments for motor and non-motor symp-
toms of PARK2-linked PD, and to shed light on its




The following primary antibodies and dilutions were used
for western blot and immunoprecipitation: mouse Parkin
(Prk8, 1:1000; Santa Cruz Biotechnology), GluN1 (1:500;
EMD Millipore), GluN2A (1:500; EMD Millipore),
GluN2B (1:500; Neuromab), GluA1 phospho-Serine 845
rabbit antibody (1:1,000; Cell Signaling Technology),
mouse tubulin (1:10,000; Sigma), rabbit tubulin (1:10,000;
Abcam), rabbit GFP (1:1000; Invitrogen), mouse Myc
(1:500; Santa Cruz Biotechnology), mouse HA (1:500;
Santa Cruz Biotechnology), and mouse Flag M2 (1:5,000;
Sigma). DyLight fluorescent secondary antibodies were
purchased from Thermo Fisher Scientific and diluted
1:15,000. The following primary antibodies and dilutions
were used for immunostaining: purified human anti-
GluN1 antiserum (a kind gift from C. Garner, German
Center for Neurodegenerative Diseases (DZNE)) with
1 μg/ml working concentration, mouse GluA1 (1:100;
EMD Millipore), rabbit Homer1 (1:500; Synaptic System),
unconjugated anti-mouse/human secondary antibody
(1:100; Invitrogen), mouse VAMP2 (1:500; Synaptic Sys-
tem), and Alexa Fluor 568/647 anti-mouse/human sec-
ondary antibody (1:400; Invitrogen). Pharmacological
agents used are as follows: cycloheximide (Calbiochem,
0.05 μg/μl, 24 h), NMDA, AP5, CNQX, and TTX (Tocris
Bioscience), bicuculline, strychnine, leupeptin (50 μM),
chloroquine (50 μM) and epoxomicin (0.1 μM)(Sigma), and
PR-619 (LifeSensors, 50 μM). Unless otherwise indicated,
all other chemicals are from Sigma-Aldrich.
Primary hippocampal culture
Rat primary hippocampal cultures were prepared using a
modified Banker culture protocol (Banker and Goslin,
1998; Waites et al., 2009). Briefly, neurons from embry-
onic (E18-E19) Sprague Dawley rat hippocampi, taken
from animals of both sexes, were dissociated in TrypLE
Express (ThermoFisher) for 20 min, washed with HBSS
(Sigma), and plated in Neurobasal medium with B27
supplement and Glutamax (all from ThermoFisher) at a
density of 250,000 neurons per well (12-well plates) or
coverslip (22 × 22 mm square).
Plasmids and transfection/transduction
The target sequence of shParkin and subcloning of
shParkin +/−human Parkin constructs into pFUGW H1
have been described previously [19]. The following plas-
mids were purchased from Addgene: pCI-SEP-GluA1/
-GluA2/-GluN1/-GluN2B (all from Dr. Robert Mali-
now), pEGFP-Parkin C431S/W403A (from Dr. Edward
Fon), pRK5-Myc-Parkin, and pRK5-HA-ubiquitin (from
Dr. Ted Dawson). Parkin mutants (T240M, R275W,
R334C, G430D) were synthesized from Genewiz and
subcloned into pEGFP-C2 and pFUGW H1-shParkin
vector. pEGFP-Parkin C431S/W403A were also sub-
cloned into FUGW H1-shParkin vector. Flag-GluN1
construct was a gift from O. Jeyifous (University of Chi-
cago). The GFP-Homer1 construct was a gift from A. M.
Grabrucker (University of Ulm, Ulm, Germany) and C.
Garner. pFUGW constructs were used to generate lenti-
virus for transduction of primary neurons as described
previously [67], except that Calfectin (SignaGen Labora-
tories) was used for transfection of HEK293T cells. HEK
medium was replaced with Neurobasal medium 18–24 h
after transfection, and this medium (viral supernatant)
was harvested 24 h later. Neurons were transduced with
50–100 μl of lentiviral supernatant per well at 2–3 days
in vitro (DIV) and used for experiments between 13 and
15 DIV. This time course was optimized based on effi-
cacy of the shRNA knockdown. Transfections were per-
formed on 5 DIV using Lipofectamine 2000 (Invitrogen)
as described previously [19].
Electrophysiology
Whole-cell patch-clamp recordings were performed in
hippocampal neurons plated onto astrocyte microislands
or 12-mm coverslips and transduced with the indicated
constructs, as previously described [19]. Cultures were
perfused at room temperature with an extracellular solu-
tion (145 mM NaCl, 5 mM KCl, 10 mM HEPES, 1.3 mM
MgCl2, 2 mM CaCl2, 10 mM glucose) containing 1 μM of
TTX (mEPSCs only) and 100 μM picrotoxin. Electrodes
had resistances between 3 and 7 MΩ containing intracel-
lular solution (110 mm Cs-methanesulfonate, 10 mM
Na-methanesulfonate, 10 mM EGTA, 1 mM CaCl2,
10 mM HEPES, 10 mM TEA, 5 mM QX-314, 5 mM
MgATP, 0.5 mM NaGTP). Neurons were visualized by
fluorescence microscopy, and those expressing GFP were
selected for recordings. For AMPA receptor current
events, neurons were held at − 65 mV and mEPSCs were
recorded over 5 min using a MultiClamp 700B amplifier
(Molecular Devices) controlled with a PC running Multi-
Clamp Commander and pClamp (Molecular Devices) and
pass filtered at 2 kHz. For miniature NMDA currents
(NMDAR-EPSCs), neurons were voltage clamped at +
40 mV and recorded over 5 min. For pharmacological in-
duction of NMDARs, currents were measured following
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local application of NMDA (100 μM; Tocris Bioscience),
using a custom-built application system ~ 200 μm from
synapsing neurons on a specific microisland, in addition
to bath application of the AMPAR antagonist CNQX
(10 μM; Tocris Bioscience) while holding the neuron at +
40 mV. Data acquisition and offline analysis of EPSCs
were performed with pClamp (Clampex version 10.4). Ap-
proximately 15–20 neurons were analyzed for each experi-
mental condition from three to four independent cultures.
Immunoblotting
Cultured neurons were collected directly in × 2 SDS
sample buffer (Bio-Rad). Samples were subjected to
SDS-PAGE, transferred to nitrocellulose membranes,
probed with primary antibodies in 5% BSA/PBS plus
0.05% Tween 20 overnight at 4 °C or 1 h at room
temperature, followed by Dylight fluorescent secondary
antibodies for 1 h. Membranes were imaged using an
Odyssey Infrared Imager (model 9120; LI-COR Biosci-
ences). Protein bands were quantified using the ImageJ
(NIH) “Gels” function, and all bands were normalized to
their loading controls.
Biotinylation assay
Cultured cortical neurons transduced with GFP/shParkin/
shParkin-WT (2–14 DIV) were washed with ice-cold PBS
containing 1 mM MgCl2 and 0.1 mM CaCl2 (PBS+) and
incubated with 1 mg/ml EZ-Link Sulfo-NHS-LC-biotin
(ThermoFisher) in PBS+ for 20 min at 4 °C with gentle
agitation. Cells were washed with ice-cold quenching buf-
fer (50 mM glycine in PBS+) for 10 min at 4 °C, lysed in
ice cold lysis buffer 50 mM Tris-base, 150 mM NaCl, 2%
Triton X-100, 0.5% deoxycholic acid, and supernatant was
incubated with streptavidin-Sepharose beads (Thermo-
Fisher) for 2 h at 4 °C. Bound proteins were immuno-
blotted with GluN1, GluN2A, GluN2B, Parkin, and
tubulin. The data were quantified by measuring surface re-
ceptor to total input receptor band intensity ratios using
ImageJ software and normalizing to GFP control cultures.
Co-immunoprecipitation assay
For co-immunoprecipitation studies, HEK293T cells were
transfected with plasmids (pCI-SEP-GluA1/-GluA2/
-GluN1/-GluN2B and Myc-Parkin for Myc-IP assay;
GFP-Homer1 and GFP control/GFP-Parkin WT/T240M/
R275W/R334C/G430D for Homer1 IP assay) using Cal-
fectin according to the manufacturer’s (SignaGen Labora-
tories) protocol. Cell lysates were collected 36 h after
transfection in lysis buffer (50 mM Tris-base, 150 mM
NaCl, 1% Triton X-100, 0.5% deoxycholic acid) with pro-
tease inhibitor mixture (Roche) and clarified by centrifu-
gation at high speed (20,000 rcf). The resulting
supernatant was incubated with Dynabeads (Thermo-
Fisher) coupled with anti-Myc or anti-Homer1 antibodies
at 4 °C under constant rotation for 2–4 h. Beads were
washed two to three times with lysis buffer and once with
PBS. Bound proteins were eluted using sample buffer
(Bio-Rad) and subject to SDS-PAGE immunoblotting.
Ubiquitination assay
HEK293T cells were transfected with pCI-SEP-GluA1/
-GluA2/-GluN1/-GluN2B, Myc-Parkin and HA-ubiquitin,
or with GFP/GFP-Parkin WT/-Parkin C431S/-Parkin
W403A/-Parkin T240M/-Parkin R275W/-Parkin R334C/
-Parkin G430D, Flag-GluN1, and HA-Ub using Calfectin
according to the manufacturer’s protocol. Thirty-six hours
after transfection, proteasome and lysosome inhibitors in-
cluding leupeptin, chloroquine, epoxomicin, and PR619
were added to the cultures. After 2–4-h treatment, cell ly-
sates were collected in lysis buffer with protease inhibitor
mixture and clarified by centrifugation at high speed
(20,000 rcf). The resulting supernatant was incubated with
Dynabeads (ThermoFisher) coupled with anti-GFP anti-
bodies or anti-Flag M2 magnetic beads (Sigma) at 4 °C
under constant rotation for overnight. Beads were washed
two to three times with lysis buffer and once with PBS.
Bound proteins were eluted using sample buffer (Bio-Rad)
and subject to SDS-PAGE immunoblotting.
Immunofluorescence microscopy
Primary antibodies and concentrations are listed above.
Alexa Fluor 488-, Alexa Fluor 568-, or Alexa Fluor
647-conjugated secondary antibodies (ThermoFisher)
were used at 1:400. Neurons were immunostained as de-
scribed previously [67]. Briefly, coverslips were fixed
with Lorene’s fixative (60 mM PIPES, 25 mM HEPES,
10 mM EGTA, 2 mM MgCl2, 0.12 M sucrose, 4% for-
maldehyde) for 15 min, primary and secondary antibody
incubations were performed in blocking buffer (2% gly-
cine, 2% BSA, 0.2% gelatin, and 50 mM NH4Cl in × 1
PBS) for 1–2 h at room temperature or overnight at 4 °
C, and all washes were done with PBS. For surface label-
ing, GluN1 (1 μg/ml) or GluA1 antibody (1:100) was
added to live neurons, incubated for 30 min at room
temperature, washed three times in PBS, and fixed
and stained with secondary antibodies as described.
Coverslips were mounted with VectaShield (Vector
Laboratories) and sealed with clear nail polish. Images
were acquired with a × 63 objective (Neofluar, NA
1.4) on a Zeiss LSM 800 confocal microscope running
Zen2 software.
GluN1 internalization assay
GluN1 internalization was measured using a protocol as
described previously [19]. Neurons expressing GFP/
shParkin/shParkin-WT were incubated with human
GluN1 antibody (1 μg/ml in PBS) for 30 min at room
temperature to label surface NMDARs, washed four
Zhu et al. BMC Biology  (2018) 16:100 Page 16 of 20
times with PBS, and either fixed immediately with Lor-
ene’s fixative or incubated at 37 °C for 15 min before fix-
ation to allow for receptor internalization. Cells were
then incubated with anti-human Alexa Fluor 647 sec-
ondary antibody diluted in blocking buffer (used for all
remaining steps) for 40 min at room temperature,
washed three times, and incubated for 30 min with un-
conjugated anti-mouse secondary (1:100) antibody to
block any remaining unlabeled cell-surface GluN1 anti-
body. Finally, cells were washed four times, perme-
abilized with 0.25% Triton X-100, and incubated for 1 h
at room temperature with anti-human Alexa Fluor 568
to label internalized GluN1.
GluN1 recycling assay
Neurons were incubated with anti-GluN1 antibody to
label surface receptors as described above and incubated
at 37 °C for 30 min to allow for receptor internalization.
All non-internalized surface antibody was subsequently
blocked with an unconjugated anti-human secondary
antibody at room temperature for 30 min and washed
four times in PBS. Next, neurons were fixed or incu-
bated at 37 °C for 1 h to allow for receptor recycling
back to the plasma membrane. They were then fixed, in-
cubated for 40 min with Alexa Fluor 568-conjugated
anti-mouse secondary antibody diluted in blocking buffer
(used for all remaining steps) to label the recycled surface
population of receptors, and washed three times. The
remaining surface primary antibodies were blocked with
an excess of an unconjugated anti-human secondary anti-
body at room temperature for 30 min, and neurons again
were washed four times. After permeabilization, neurons
were incubated with Alexa Fluor 647-conjugated
anti-human secondary antibody for 40 min to label the in-
ternalized population of receptors, washed three times,
and mounted and imaged as described previously.
Chemical LTP/LTD assay
Chemical LTP/LTD assay was performed as described
previously [68]. Neurons were washed twice in Tyrodes
solution (120 mM NaCl, 2 mM CaCl2, 2.5 mM KCl,
25 mM HEPES, 30 mM glucose, pH 7.4), and then incu-
bated in cLTP buffer (200 μM glycine, 1 μM strychnine,
20 μM bicuculline in Tyrodes solution, pH 7.4) for
5 min. Following a quick wash with wash buffer (2 mM
MgCl2, 50 μM AP5, 10 μM CNQX, 0.5 μM TTX, 1 μM
strychnine in Tyrodes solution, pH 7.4), neurons were
incubated for another 5 min in this buffer prior to fix-
ation. For chemical LTD, neurons were washed twice in
Tyrodes solution, then incubated with cLTD buffer
(25 μM NMDA, 1 μM strychnine, 0.5 μM TTX, 10 μM
glycine in Tyrodes solution, pH 7.4) for 5 min followed
by a quick wash with wash buffer. After cLTP or cLTD
treatment, neurons were subjected to surface GluA1
staining for 10 min, then fixed and immunostained with
secondary antibody.
Image analyses
Images of surface or total GluN1/GluA1 were manually
thresholded to select only puncta that were greater than
twofold above image background. The average intensity
values of puncta were measured using the “Analyze Par-
ticles” function in ImageJ/Fiji, with puncta size set be-
tween 2 and 100 pixels. Intensity of Homer1 puncta at
sites of VAMP2 colocalization was calculated by creating
a selection in ImageJ/Fiji using the VAMP2 channel, ap-
plying it to the relevant Homer1 channel, and measuring
average intensity values of Homer1 puncta using the
Analyze Particles function, with puncta size set between
2 and 100 pixels. For internalization and recycling as-
says, ratios of internalized GluN1 intensity to surface
GluN1 intensity, or recycled to internalized GluN1 in-
tensity, were calculated per punctum (after measuring
raw intensity values in the red and far-red channels) and
averaged for each field of view. These averaged ratios
were then normalized to the control condition (average
value set to 1) and expressed as a fraction of control.
Statistical analysis
Statistical analyses were performed in GraphPad Prism5
software using either one-way ANOVA-Tukey, ANOVA-
Dunnett’s multiple comparison test, or unpaired, two-tailed
Student’s t tests, with P < 0.05 considered significant. Data
are presented as mean ± SEM.
Additional files
Additional file 1: Figure S1. Expression of Parkin mutants in hippocampal
neurons. (a) Schematic diagram of Parkin showing domains and mutation/
deletion sites. (b) Immunoblots of lysates from 14 DIV hippocampal neurons
expressing GFP control, shParkin, shParkin-WT, shParkin-T240M, shParkin-
R275W, shParkin-R334C, or shParkin-G430D constructs, probed for Parkin, GFP,
and tubulin. (c) Representative images of shParkin-WT, shParkin-T240M,
shParkin-R334C, shParkin-R275W and shParkin-G430D expression in 14 DIV
hippocampal neurons. Scale bar, 10 μm. (d) Immunoblots of lysates from 14
DIV Parkin KO hippocampal neurons expressing shParkin, shParkin-WT,
shParkin-T240M, shParkin-R275W, shParkin-R334C or shParkin-G430D constructs
and Parkin KO control, probed for Parkin, GFP, and tubulin. (e) Immunoblots
of lysates from hippocampal neurons expressing GFP, shParkin, shParkin-WT,
shParkin-C431S, or shParkin-W403A, probed for Parkin, GFP, and tubulin. Note
that GFP-Parkin W403A is not recognized by the Parkin antibody but
is detected by the GFP antibody. (PDF 3931 kb)
Additional file 2: Figure S2. Parkin deficiency leads to reduced
NMDAR-mediated currents and cell-surface levels. (a) Representative
traces of whole-cell currents (upper panel) induced by local application
of 100 μM NMDA to hippocampal neurons expressing GFP, human Parkin
(Hu-Parkin), shParkin, or shParkin-WT constructs, and quantification of
peak current amplitudes induced by NMDAR activation for these conditions
(lower panel) (n = 19 for control, 24 for shParkin, 22 for hu-Parkin, 14 for
rescue; *P < 0.05, **P < 0.005, one-way ANOVA, error bars represent SEM). (b)
Representative immunoblots of total input (left) and surface biotin-labeled
fractions (right) from 14 DIV hippocampal neuron lysates expressing GFP,
shParkin or shParkin-WT constructs. (c) Quantification of surface/input ratio,
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normalized to GFP control condition and expressed as a fraction of control.
(n = 3 experiments; *P < 0.05; **P < 0.01, ***P < 0.001, unpaired t test, error
bars represent SEM). (PDF 215 kb)
Additional file 3: Figure S3. Homer1 overexpression does not rescue
cell-surface NMDAR levels in Parkin knockdown neurons. (a) Representative
images of hippocampal neurons co-transfected from 6 to 14 DIV with
mCherry +/− shParkin alone or with GFP-Homer1, and immunostained for
surface GluN1. Scale bar, 10 μm. (b) Quantification of cell surface GluN1,
expressed as a fraction of mCherry control (n ≥ 40 fields of view per
condition with > 100 GluN1 puncta per field, results confirmed in 3
independent experiments. ***P < 0.001, one-way ANOVA, error bars
represent SEM). (PDF 5670 kb)
Additional file 4: Figure S4. Parkin-mediated ubiquitination does not
induce NMDAR degradation. (a) Representative immunoblots for GFP
immunoprecipitation (IP) under denaturing conditions (1% SDS) from
HEK293T cell lysates expressing Myc/Myc-Parkin, GFP-GluN1 and HA-
ubiquitin, probed for HA and GFP. Ubiquitin immunoreactivity used for
quantification is marked on HA blots. (b) Quantification of GFP-GluN1
ubiquitination by measurement of marked HA blot intensity, normalized
to immunoprecipitated GFP-GluN1 and reported as a fraction of Myc
control. (n = 3 experiments, *P < 0.05; one-way ANOVA, error bars
represent SEM). (c) Representative immunoblots of lysates from 14 DIV
hippocampal neurons expressing GFP/shParkin/shParkin-WT constructs,
treated with DMSO vehicle control (−) or cycloheximide (CHX) and
probed with the indicated antibodies. (d) Quantification of protein intensity
after 24 h of CHX treatment, normalized to tubulin and reported as a
fraction of the DMSO control intensity (starting material) (n = 3 experiments,
unpaired t test, error bars represent SEM). (PDF 178 kb)
Additional file 5: Figure S5. Parkin has no effect on phospho-Serine
845 GluA1 reduction during cLTD. (a) Representative immunoblots of
lysates from 14 DIV hippocampal neurons expressing GFP/shParkin/sh
Parkin-WT/-T240M/-R334C constructs, under control condition (−) or after
cLTD induction (+) and probed with the indicated antibodies. (b)
Quantification of the ratio of phospho-Serine 845 GluA1 intensity with
cLTD to control condition, normalized to GFP control. (n = 3 experiments,
one-way ANOVA, error bars represent SEM). (PDF 119 kb)
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